Verastem to make strategic deal in future, says Oppenheimer

theflyonthewall.com

Oppenheimer expects Verastem to make continued progress on its cancer treatment, providing increasing validation for its platform. The firm thinks the company will ultimately make a strategic deal, and it views the stock as a compelling long-term investment. Oppenheimer maintains a $16 price target and Outperform rating on the stock.

View Comments